Treatment of cardiogenic shock



Similar documents
Inpatient Heart Failure Management: Risks & Benefits

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie 1

Inotropes/Vasoactive Agents Hina N. Patel, Pharm.D., BCPS Cathy Lawson, Pharm.D., BCPS

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa Objectives. No disclosures, no conflicts

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Chapter 16. Learning Objectives. Learning Objectives 9/11/2012. Shock. Explain difference between compensated and uncompensated shock

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE

ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

Septic Shock: Pharmacologic Agents for Hemodynamic Support. Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident

The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias

Cardiogenic shock: invasive and non-invasive monitoring John T. Parissis Attikon University Hospital Athens, Greece

Atrial Fibrillation Management Across the Spectrum of Illness

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

Acute heart failure may be de novo or it may be a decompensation of chronic heart failure.

INTRODUCTION TO EECP THERAPY

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Medical Direction and Practices Board WHITE PAPER

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, Participating Faculty

Vasopressors. Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco

PULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

STAGES OF SHOCK. IRREVERSIBLE SHOCK Heart deteriorates until it can no longer pump and death occurs.

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

Anaesthesia and Heart Failure

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Rikshospitalet, University of Oslo

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

Drug Treatment in Type 2 Diabetes with Hypertension

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

ECG may be indicated for patients with cardiovascular risk factors

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA

Non-Invasive Positive Pressure Ventilation in Heart Failure Patients: For Who, Wy & When?

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

Current strategies for the prehospital care of congestive heart failure

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Perioperative Cardiac Evaluation

Drug treatment of elevated blood pressure

Medical Tourism - The Role of Intervals inCardiovascular Cancer

How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy

Section Four: Pulmonary Artery Waveform Interpretation

All Patient Refined DRGs (APR-DRGs) An Overview. Presented by Treo Solutions

Cardiovascular Guidelines for DOT Physical Exams By Maureen Collins MSN, APRN, BC

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Update on Small Animal Cardiopulmonary Resuscitation (CPR)- is anything new?

A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation

James F. Kravec, M.D., F.A.C.P

Dr Kenneth Tan. MBBS MMed(Anaes) MRCP(UK) EDIC FCCP Anesthesia and Intensive Care Services Mount Elizabeth Hospital

The new Heart Failure pathway

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it.

ACLS PHARMACOLOGY 2011 Guidelines

Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy. Medical Policy

Atrial Fibrillation An update on diagnosis and management

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

1 Congestive Heart Failure & its Pharmacological Management

ACLS PRE-TEST ANNOTATED ANSWER KEY

Exchange solutes and water with cells of the body

Antiplatelet and Antithrombotics From clinical trials to guidelines

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery

11/2/2015 Domain: Care Coordination / Patient Safety

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology

Kardiogent shock. FYA-kursus 28. November 2006

Sepsis: Identification and Treatment

Cardiovascular Disease and Maternal Mortality what do we know and what are the key questions?

Procedure for Inotrope Administration in the home

Acute heart failure syndrome

Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology

National Imaging Associates, Inc. Clinical guidelines

Milwaukee School of Engineering Case Study: Factors that Affect Blood Pressure Instructor Version

Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis. Michael A. Blazing

VASOPRESSOR AGENTS IN SEPTIC SHOCK

Presenter Disclosure Information

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39

3/2/2010 Post CABG R h e bili a i tat on Ahmed Elkerdany Professor o f oof C ardiac Cardiac Surgery Ain Shams University 1

Heart Disease: Diagnosis & Treatment

Statement on Disability: Pulmonary Hypertension

BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC FAX

1. The potential sites of action for sympathomimetics and the difference between a direct and indirect acting agonist.

Advantages of rate control Disadvantage of rate control Advantages of rhythm control Disadvantages of rhythm control

F.E.E.A. FONDATION EUROPEENNE D'ENSEIGNEMENT EN ANESTHESIOLOGIE FOUNDATION FOR EUROPEAN EDUCATION IN ANAESTHESIOLOGY

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Physician and other health professional services

Cardiovascular diseases. pathology

Transcription:

ACUTE HEART FAILURE AND COMORBIDITY IN THE ELDERLY Treatment of cardiogenic shock Christian J. Wiedermann, M.D., F.A.C.P. Associate Professor of Internal Medicine, Medical University of Innsbruck, Austria Director, Department of Internal Medicine, Central Hospital of Bolzano (BZ), Italy

Cardiovascular findings in hospitalized heart failure in the ED «Euro Heart Failure Survey» Acute dyspnea Other signs of decompensation Stabile heart failure MCI / unstabile angina Tachycardic atrial fibrillation Asymptomatic LV dysfunction Ventricular arrhythmias Cardiogenic shock Cardiac arrest ED = emergency department, MCI = Myocardial infartion, LV = left ventricular dysfunction Cleland JG, et al. Eur Heart J 2003; 24:442 463 Patients (%)

Acute heart failure syndrome (AHFS) AHFS leading cause of hospitalization among patients >65 years of age 1 Highest costs related to heart failure Sentinel prognostic event 2 recurrent hospitalization 50% at 6 months 1-year mortality 30% Patient profile characterized by comorbidities Hypertension, chronic kidney disease Hyponatremia, anemia COPD 1 Go AS, et al. Circulation 2013;127:e6-245. 2 Kociol RD, et al. Am Heart J 2010;160:885-92.

Triggers of AHFS 1 Nonadherence medication regimen, sodium or fluid restriction Acute myocardial ischemia Uncorrected high blood pressure AF and other arrhythmias Recent addition of negative inotropic drugs verapamil, nifedipine, diltiazem, beta blockers Pulmonary embolus De Keulenaer GW. Circulation 2009; 119:3044 6.

Triggers of AHFS 2 Initiation of drugs that increase salt retention steroids, glitazones, NSAIDs Excessive alcohol or illicit drug use Endocrine abnormalities thyroid disorders, diabetes mellitus Concurrent infections Additional acute cardiovascular disorders valve disease, aortic disease, endo-, myo- or pericarditis De Keulenaer GW. Circulation 2009; 119:3044 6.

ESC 2005 Classification of AHFS HF = heart failure, AHF = acute heart failure, ACS = acute coronary syndrome Adapted from Filippatos & Zannad. Heart Fail Rev 2007; 12:87 90.

Mortality (%) AHFS Hospital All-cause Mortality (6,4 %) by Clinical Profile at Entry «Italian Registry» 60 50 40 30 20 10 3,2 4,1 6,1 6,2 13 23,8 Hypertension Decompensated HF Right HF Pulmonary Edema ACS Cardiogenic Shock 0 AHFS AHFS = acute heart failure syndrome, HF = heart failure, ACS = acute coronary syndrome Oliva F, et al. Eur J Heart Fail 2012; 14:1208 17.

AHFS in the Emergency Department Diagnosis, treatment, and disposition 80% of ED patients with AHFS hospitalized Achieve hemodynamic balance Improve functional capacity Decrease mortality and length of stay decompensation of underlying, chronic HF shock, arrhythmias, or ST-segment myocardial infarction AHFS = acute heart failure syndrome, ED = emergency department Peacock WF. Cardiol Clin. 2005; 23:569 88, viii.

Suspected AHFS in the Emergency Department Hypotensive AHFS Yes Cardiogenic shock or symtomatic hypotension No Perform history and physical exam Yes Consider other differential diagnosis No Hypoperfusion (cool extremities) or altered mental status No Hypertensive AHFS Normotensive AHFS Adapted from Collins S, et al. Ann Emerg Med 2007; 51:45-57.

In-hospital Mortality Rates by Admission SBP Deciles in AHFS (n = 48.567) In-hospital Mortality (%) 9,6 12 10 8 5,6 4,6 3,7 3,2 2,7 2,3 2 2 1,6 6 4 2 0 Admission SBP Decile [mmhg] SBP = systolic blood pressure, AHFS = acute heart failure syndrom Gheorgiade M, et al. JAMA 2006; 296:2217-26.

Independent predictors of AHFS all-cause hospital mortality «Italian Registry» CI = confidence interval, SBP = systolic blood pressure Oliva F, et al. Eur J Heart Fail 2012; 14:1208 17.

Cardiogenic Shock Consequence of cardiac pump failure CO decreases PCWP increases Pathophysiology compensates for diminished CO to maintain perfusion to vital organs SVR increases CO = cardiac output, SVR = systemic vascular resistance, PCWP = pumonary capillary wedge pressure

Low Perfusion (CI ) Yes No Clinical Destinction of AHFS Congestion (PCWP ) No Yes Warm and Dry Warm and Wet Diuretics Nitrates Cold and Dry Cold and Wet Inotropes evtl. Nitrates evtl. Vasopressors PCWP = pulmonary capillary wedge pressure, CI = cardiac index Nohria A, et al. JAMA 2002;287:628 40.

Treatment of AHFS with hypotension, hypoperfusion or shock PDE = phosphodiesterase Electrical cardioversion Inotrope (eg, dobutamin) Short-term mechanical support Levosimendan/PDE-Inhibitor Vasopressor (eg, dopamin) McMurray JJ, et al. Eur J Heart Fail 2013; 15:361-2.

Proposed algoritm for use of IV drugs in AHFS Oxygen / NIV Loop diuretic ± vasodilator Clinical evaluation SBP > 100 mmhg SBP 90 100 mmhg SBP < 90 mmhg Vasodilator (nitroglycerin, nitroprusside, nesiritide) Vasodilator and/or inotrope (dobutamine, PDEI, levosimendan) Consider preload correction with fluids then inotropes IV = intravenous, NIV = non-invasive ventilation, SBP = systolic blood pressure, PDEI = phosphodiesterase inhibitor Lemasle L, et al. Annual Update Intens Care Emerg Med 2013; pp. 237-47.

Dobutamine in AHFS Meta-analysis Tacon CJ. Intensive Care Med 2012; 38:359-67.

Levosimendan vs. Placebo in AHFS Meta-analysis Delaney A, et al. Int J Cardiol 2010; 138:281 9.

Levosimendan vs. Dobutamin in AHFS Metaanalysis Delaney A, et al. Int J Cardiol 2010; 138:281 9.

Mechanism of action of inotropes ER = endoplasmatic reticulum, C/I/T = troponin C/I/T, P = phophsor Jannsens U. Med Klin Intensivmed Notfmed 2012; 107:397 425.

23 RCTs with 3212 hypotensive shock patients and 1629 deaths Six vasopressors in 11 comparisons No difference in mortality between norepinephrine and dopamine Dopamine increases risk for arrhythmia Choice of vasopressors does not influence the outcome Havel C, et al. Cochrane Database Syst Rev 2011; May 11:CD003709.

Low Perfusion Yes No Clinical Destinction of AHFS No Congestion Yes Warm and Dry Warm and Wet Cold and Dry Cold and Wet Volume Nohria A, et al. JAMA 2002;287:628 40.

hypotension Cardiac Index Frank-Starling-based Treatment of AHFS normal Moderate HF Severe HF LV Filling Pressure pulmonary edema 1a = Volume resuscitation, 2a = Diuretics/vasodilators, 3a = Inotropes LV = left ventricular, HF = heart failure Modif. after Wollert KC & Drexler H. Internist (Berl) 1998; 39:459 66.

Summary and Conclusions In AHFS, hypotensive elderly patients with comorbidities are at the highest risk of death. Correction of triggering events, rapid stabilization of hemodynamics and improvement of symptoms and respiratory status are important goals. Electrical cardioversion, diuretics, vasodilators have good evidence for efficacy when indicated. Use of inotropes and vasopressors are of limited value.